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Abstract 
 
Objective. The objective of this medication utilization evaluation (MUE) was to determine the appropriateness of 
dabigatran and rivaroxaban while also reviewing outcomes for safety and effectiveness within a large, multi-center health 
system.    
Methods.  A retrospective chart review was performed using the system’s electronic medical record.  A data inquiry was 
requested and generated for dabigatran usage from July 28, 2011 through July 28, 2012 and for rivaroxaban from March 
1, 2012 to July 31, 2012 at eight health system hospitals.  All patients receiving at least one dose were eligible for 
inclusion in the MUE. 
Results.  For dabigatran, 78 of 390 unique patient encounters were analyzed (20%).  All 62 rivaroxaban encounters were 
included in the analysis.  Dabigatran was used for appropriate indications in 94% of encounters and 82% for rivaroxaban. 
Based on indication and renal function, 87% of dabigatran patients and 92% of rivaroxaban patients received correct 
dosing. For patients transitioning to or from another anticoagulant, appropriate transitions occurred in 44% of dabigatran 
transitions and 48% of rivaroxaban transitions.  At discharge, 83% of dabigatran and 86% of rivaroxaban therapy was 
continued. There were no reported strokes or systemic embolism with dabigatran, but one reported deep vein thrombosis 
occurred during hospitalization with rivaroxaban therapy.  Documented bleeds in 5% of dabigatran and 3% of rivaroxaban 
patients. Patient education was documented for 37% of dabigatran and 26% of rivaroxaban patients receiving therapeutic 
anticoagulation.      
Conclusion.  This MUE revealed the appropriate use of dabigatran and rivaroxaban therapy with few safety outcomes 
within a large, multi-center health system.  
Introduction 
New oral anticoagulants have created excitement 
as potential replacements for warfarin therapy in the 
treatment and prevention of thromboembolism.  In 2010, 
dabigatran etexilate (Pradaxa
®
), an oral direct thrombin 
inhibitor, received Federal Drug Administration (FDA) 
approval for the prevention of stroke and systemic 
embolism in patients with non-valvular atrial fibrillation.
1
  
In 2011, rivaroxaban (Xarelto
®
) was FDA approved as the 
first oral factor Xa inhibitor for the reduction of stroke 
and systemic embolism in patients with non-valvular 
atrial fibrillation and for post-operative venous 
thromboembolism (VTE) prophylaxis in patients 
undergoing knee and hip replacement surgery.
2
  
Additionally, in 2012, rivaroxaban received FDA 
approval for the treatment of deep-vein thrombosis (DVT) 
and pulmonary embolism (PE).
3
  The new oral 
anticoagulants are appealing alternatives to current 
standard therapy, with demonstrated non-inferiority for 
thromboembolic indications and less stringent 
monitoring.
4-11
  
The efficacy of dabigatran was demonstrated in 
the Randomized Evaluation of Long-Term 
Anticoagulation Therapy (RE-LY) trial comparing 
dabigatran against warfarin in the prevention of stroke 
and systemic embolism in non-valvular atrial fibrillation.  
Dabigatran 150 mg by mouth twice daily was superior to 
warfarin therapy in reduction of stroke and systemic 
embolism, but the incidence of major bleeding was 
similar.
4
  Rivaroxaban demonstrated non-inferiority to 
warfarin in the reduction of stroke and systemic embolism 
in patients with non-valvular atrial fibrillation in the 
Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 
Compared with Vitamin K Antagonism for Prevention of 
Stroke and Embolism Trial in Atrial Fibrillation 
(ROCKET AF).
5
  For VTE prophylaxis, as shown in the 
Regulation of Coagulation in Orthopedic Surgery to 
Prevent Deep Venous Thrombosis and Pulmonary 
Embolism (RECORD) trials, rivaroxaban illustrated 
superiority over enoxaparin in the prevention of DVT, PE, 
and mortality in patients undergoing total hip arthroplasty 
(THA) and total knee arthroplasty (TKA). 
6-9
  The 
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EINSTEIN investigators exemplified rivaroxaban non-
inferiority to warfarin for the initial and continued 
treatment of DVT and PE events with similar bleeding 
risks.
10,11
  The manufacturer recommended dosing for 
approved indications is listed in Table 1.
1,2
  
With the advent of these new agents, transitions 
between anticoagulants hold the potential for serious 
medication errors.  Appropriate transitions between 
agents are essential to optimize care and reduce morbidity 
and mortality.  Conversion to or from dabigatran or 
rivaroxaban requires monitoring and caution is necessary 
to minimize thromboembolic and bleeding complications.  
Table 1 provides the manufacturer recommended 
transitions between available anticoagulants.
1,2
    
Lastly, while both dabigatran and rivaroxaban 
have shown efficacy in reducing the risk of systemic 
thromboembolism, potential side effects, including 
bleeding, are an inherent risk with these medications.  The 
Adverse Events Reporting System (AERS) database has 
noted bleeding as a commonly reported complication with 
dabigatran and rivaroxaban therapy.
12,13
  
Dabigatran and rivaroxaban were added to the 
Indiana University Health system formulary with orderset 
development on March 1, 2011 and March 1, 2012, 
respectively.   Upon addition to the formulary, both 
medications required a mandatory orderset to initiate 
therapy due to the inherent risks associated with 
anticoagulant therapy.  A medication utilization 
evaluation (MUE) was performed at eight hospitals within 
the large multi-center health system.  The primary 
objective of this MUE was to determine the 
appropriateness of dabigatran and rivaroxaban use while 
also reviewing potential outcomes for safety and 
effectiveness within a large, multi-center health system.    
  
Methods 
A retrospective chart review was performed using 
the system’s electronic medical record (EMR).  A data 
inquiry was requested and generated for dabigatran usage 
from July 28, 2011 through July 28, 2012 and for 
rivaroxaban from March 1, 2012 to July 31, 2012 at eight 
IUH hospitals.  Search terms for the inquiry included 
“dabigatran”, “Pradaxa®”, “rivaroxaban”, and “Xarelto®.”  
All dosage strengths for each anticoagulant were included 
in this chart review.  Patients receiving at least one dose 
during their hospital stay were eligible for inclusion.  An 
online random number generator was used to select 
dabigatran encounters for review.  IRB approval was 
obtained from Indiana University.  
 Data extracted from the EMR included patient 
demographics (age, weight, and baseline renal function), 
indication, utilization prior to admission, inpatient dosage 
strength, number of doses administered, appropriateness 
of dose, assessment for appropriate monitoring of 
laboratory data, transitioning between anticoagulants, 
discharge regimen, reason for discontinuation, 
documented thromboembolism or bleeding, and 
documentation of anticoagulant education.  The indication 
for use was collected from provider clinical notes and was 
evaluated for appropriateness based on FDA approved 
indications at the time of the study period.  Utilization 
prior to admission was gathered from the admission note 
or admission medication history.  The inpatient dose was 
defined as the dose most frequently received by the 
patient during hospitalization.  Doses were evaluated as 
appropriate based on renal function and manufacturer 
recommended dosing for prophylactic or therapeutic 
indications. Specific reasons for discontinuation, 
documented bleeding, and thromboembolic events were 
collected from practitioners’ clinical notes in the EMR.  
Based on system protocols, appropriate 
monitoring was defined as baseline hemoglobin and at 
least once weekly and serum creatinine at baseline and at 
least every four days.  Serum creatinine was used to 
assess renal function by calculation of the creatinine 
clearance (CrCl) utilizing the Cockcroft-Gault equation.  
Dosing was considered appropriate based on the dosing 
adjustments recommended by the manufacturers in Table 
1.  Transitional therapy between anticoagulants was 
evaluated utilizing the electronically reported medication 
administration times documented by nursing staff.  
Transitions were determined appropriate and 
inappropriate utilizing manufacturer recommended 
transitions (Table 1).
1,2
  Concomitant administration of 
antiplatelet agents was not considered duplicate 
anticoagulation.  Statistical analysis was performed using 
descriptive statistics.   
 
Results  
The data query produced 390 dabigatran orders 
with 20% (n=78) encounters analyzed.  The query 
resulted in 62 rivaroxaban encounters and all rivaroxaban 
patient data was reviewed (n=62). Baseline characteristics 
are listed in Table 2.  
When assessing use prior to hospital admission, 
62% (n=48) of dabigatran patients and 24% (n=15) of 
rivaroxaban patients were receiving the medication as an 
outpatient. According to package labeling at the time of 
the study, use for appropriate indications occurred in 94% 
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(n=73) of dabigatran and in 82% (n=51) of rivaroxaban 
encounters.  Indications for use of dabigatran and 
rivaroxaban are shown in Table 3.  It is worth noting that, 
38% of the off-label uses during hospitalization were 
continuation of home therapy occurring in four of five 
dabigatran and two of eleven rivaroxaban encounters. 
Information on inpatient dosing is provided in 
Table 4. Based on indication along with renal function, 
87% (n=68) of dabigatran patients and 92% (n=57) of 
rivaroxaban patients received correct dosing per the 
manufacturer.
1,2  
Continuation of home doses occurred in 
60% (n=9) of the incorrect dosing encounters with seven 
out of ten incorrect for dabigatran and two out of five for 
rivaroxaban.  Inappropriate renal adjustment was the 
cause of all incorrect dabigatran doses and 80% (n=4) of 
incorrect rivaroxaban dosing encounters.  Appropriate 
hemoglobin and serum creatinine monitoring occurred in 
97% (n=76) of dabigatran encounters and 87% (n=54) for 
rivaroxaban.   
While the dosing was appropriate for a majority 
of patients, there were concerns with the transitions 
between the new oral anticoagulants and conventional 
anticoagulants (Figure 1).  For dabigatran, transitioning to 
or from another anticoagulant occurred in 46% (n=36) of 
patients with only 44% (n=16) appropriate.
1
  There were 
37% of encounters (n=23) in which patients were 
transitioned between another anticoagulant and 
rivaroxaban.  Of the 23, there were 48% (n=11) with 
correct transitions as recommended by the manufacturer.
2
  
At discharge, 83% (n=65) of dabigatran and 86% 
(n=53) of rivaroxaban therapy was continued. For patients 
being discharged on dabigatran, 94% (n=61) had 
dabigatran prescribed for an FDA approved indication 
and 91% (n=59) had correct dosing based on indication 
and renal function.  Rivaroxaban patients upon discharge 
had an FDA approved indication in 85% of encounters 
(n=45) and 94% (n=50) had correct dosing based on 
indication and renal function.   
For patients with therapy discontinued prior to 
discharge, reasons included: transitioning to other 
anticoagulants, worsening renal function, death, 
thromboembolic and bleeding complications, and 
completion of anticoagulant therapy.  There were no 
reported strokes or systemic embolism in patients 
receiving dabigatran.  There was one death in a patient 
receiving dabigatran, but the death was contributed to 
pulmonary complications unrelated to dabigatran therapy.  
One VTE occurred during hospitalization in patients 
receiving rivaroxaban therapy.  Bleeding resulted in the 
discontinuation of therapy in three dabigatran and one 
rivaroxaban patients, but there were documented bleeds in 
5% (n=4) of dabigatran patients and 3% (n=2) of 
rivaroxaban patients.  Patient education prior to discharge 
was performed for 37% (n=29) of dabigatran encounters 
and 26% (n=8) of rivaroxaban patients receiving 
therapeutic doses.   
 
Discussion  
With any new medication release, post-marketing 
surveillance is crucial to evaluate its use within clinical 
practice along with potential safety and effectiveness 
outcomes.  The recent Anticoagulation Forum consensus 
statement recommends monitoring of quality indicators to 
assess patient outcomes and identify areas for 
improvement.
14
 Due to the intrinsic bleeding risks and 
potential for thromboembolic events, the new oral 
anticoagulants must be assessed in a clinical setting.  This 
combined MUE for dabigatran and rivaroxaban reviewed 
the utilization of these new oral anticoagulants within a 
large, multi-center health system.   
Overall, dabigatran and rivaroxaban therapy were 
prescribed and dosed appropriately in the majority of 
patients.  These anticoagulants were used for FDA 
approved indications in 89% of encounters.  It is worth 
noting that during the study period, rivaroxaban had not 
yet received FDA indication for the treatment of DVT or 
PE.  Treatment with rivaroxaban for these indications was 
deemed inappropriate for this MUE.  Additionally, similar 
safety profiles were revealed for dabigatran and 
rivaroxaban, when compared to larger clinical trials.
4-11
  
Non-major bleeding complications occurred in 5% of 
non-valvular atrial fibrillation patients on dabigatran, less 
than the 30% of patients who reported major or minor 
bleeding in the RE-LY trial.
4 
 Rivaroxaban bleeding 
occurred in 3.2% of patients in this study, with one patient 
status post TKA and the other with atrial fibrillation.  This 
is comparable to the 3.3-6.6% of combined major and 
minor bleeding in the RECORD trials and less than the 
14.9% seen in the ROCKET-AF.
5-9
  Bleeding 
complications were likely lower than reported in clinical 
trials due  to the retrospective surveillance used in this 
chart review, as compared to extensive observation during 
the RE-LY and ROCKET-AF trials. 
Excluding bleeding events, few other 
complications occurred in patients evaluated for this 
MUE.  There was one documented death for a patient 
receiving dabigatran, but this was contributed to 
pulmonary complications unrelated to dabigatran use. 
There were no reports of stroke or systemic embolism 
during hospitalization in the dabigatran arm and one 
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report of a post-operative DVT in a patient receiving 
prophylactic rivaroxaban.  This encounter lead to a 
similar VTE rate, when compared to the incidence in the 
four RECORD trials (3.6% vs. 1-10% respectively).
6-9
 
Appropriate transitions between anticoagulant 
therapies are imperative to reduce the risk of 
thromboembolism and bleeding and this MUE revealed 
concerns in transitioning between anticoagulants.  While 
delays in therapy during a transition between agents 
occurred with both anticoagulants, no delays resulted in a 
thromboembolism.  Inappropriate transitions from this 
MUE revealed dual anticoagulants and administration of 
new anticoagulants too soon after discontinuation of 
previous therapy, enhancing the bleeding risk.  This was 
demonstrated as one of the rivaroxaban minor bleeds 
occurred in a patient where rivaroxaban therapy was 
initiated six hours after receiving enoxaparin.  Since 
practitioners often have less experience with these new 
anticoagulants, it is vital to educate on proper transitions 
between anticoagulants to enhance the safety and 
effectiveness of dabigatran and rivaroxaban.   
Finally, due to potential bleeding and 
thromboembolic complications inherent with all 
anticoagulants, patient counseling is imperative.  The 
overall rate of anticoagulation patient education for 
therapeutic indications for both anticoagulants was only 
34% in this MUE.   The Joint Commission recommends 
patient education for all therapeutic anticoagulants prior 
to discharge.
14 
 Additionally, the Anticoagulation Forum 
stresses the importance of patient education counseling to 
enhance the safe and effective use of these anticoagulants 
in the post-discharge process.
15   
Patient education in the 
hospital setting is vital to ensure appropriate utilization 
and understanding of these medications.   Educational 
instructions may include proper medication 
administration, compliance, monitoring, drug and food 
interactions, and potential adverse reactions from 
anticoagulant therapy.  Patient education continues to be a 
focus for pharmacists to ensure patients are adequately 
informed of their therapy, potentially minimizing 
thromboembolic and bleeding complications.  
 
 This MUE is the first to evaluate the use of these 
medications within a large, multi-center health system; 
however, it is not without limitations.  Due to the large 
number of patients receiving dabigatran, encounters were 
randomly selected and not all patients who received doses 
were reviewed in this analysis.  Patients were only 
considered for inclusion if they had an order for 
dabigatran or rivaroxaban.  Therefore, all bleeding and 
thromboembolic complications may not have been 
evaluated as there could have been patients who had the 
medication held or discontinued during their entire 
hospitalization. Also, the indication and continuation of 
home therapy was dependent upon reliable clinical notes 
and admission medical histories.  Furthermore, no sub-
group analysis was performed to identify risk 
characteristics for the safety and efficacy outcomes.  
Lastly, with the retrospective nature of this study, there 
was no follow-up assessment after hospital discharge, 
making it difficult to determine the true bleeding and 
thromboembolic complications.    
As a result of this MUE, health system changes 
were implemented to improve the safe and effective use 
of these oral anticoagulants.  The orderset for both of 
these anticoagulants was updated to reinforce the FDA 
approved indications and dosing, along with manufacturer 
recommended transitions between anticoagulants.  To 
increase patient education, an alert was built to notify 
pharmacists to educate patients on these new oral 
anticoagulants prior to discharge.  Continued evaluation 
of patients on these oral anticoagulants will determine the 
final impact of this MUE on the health-system. 
 
Conclusion 
This medication utilization evaluation within a 
large, multi-center health system focused on the 
utilization of dabigatran and rivaroxaban therapy.  
Anticoagulant therapy was appropriate for most 
encounters, utilizing FDA approved indications and 
dosing recommendations.  In addition, rates of bleeding 
and thromboembolism were less than or similar compared 
to clinical trials.  However, quality improvement efforts 
have been implemented to improve the appropriate and 
safe use of these anticoagulants. Overall, this medication 
utilization evaluation revealed the appropriate use of 
these new oral anticoagulants within this health system 
with few safety outcomes.   
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Table 1: Dosing and Transitions between Anticoagulants 
 
CrCl = creatinine clearance; BID = twice daily; TKA = total knee arthroplasty;  
THA = total hip arthroplasty; DVT = deep vein thrombosis; PE = pulmonary embolism;  
INR = international normalized ratio; UFH = unfractionated heparin  
 Dabigatran
1 
Rivaroxaban
2 
Dosing Recommendations 
Non-valvular 
atrial fibrillation 
 CrCl > 30 mL/min: 150 mg orally BID 
 CrCl 15-30 mL/min: 75 mg orally BID 
 CrCl > 50 mL/min: 20 mg orally daily 
 CrCl 30-50 mL/min: 15 mg orally daily 
TKA/THA  
post-operative 
prophylaxis  
 
 CrCl > 30 mL/min: 10 mg orally daily  
DVT/PE 
Treatment 
 
 CrCl > 50 mL/min: 15 mg orally BID 
for 3 weeks then 20 mg orally daily 
 CrCl 30-50: 15 mg orally BID for 3 
weeks then 15 mg orally daily 
Anticoagulation Transitioning  
Warfarin 
 
 From warfarin, discontinue warfarin must 
be discontinued and initiate dabigatran 
started when INR < 2.0 
 To warfarin:  
o CrCl > 50 mL/min: discontinue 
dabigatran 3 days after starting warfarin 
o CrCl of 31-50 mL/min:  discontinue 
dabigatran 2 days after starting warfarin  
o CrCl of 15-30 mL/min:   discontinue 
dabigatran 1 day after starting warfarin   
 From warfarin, discontinue warfarin 
and start rivaroxaban when INR < 3.0 
 To warfarin, initiate warfarin 24 hours 
after discontinuing rivaroxaban  and 
bridge with a parenteral anticoagulant 
until INR is therapeutic  
UFH 
 From UFH, initiate dabigatran at the time 
of UFH discontinuation  
 To UFH, discontinue dabigatran and 
initiate UFH based on estimated CrCl: 
o CrCl > 30 mL/min: wait 12 hours after 
last dose of dabigatran  
o CrCl 15-30 mL/min:  wait 24 hours 
after last dose of dabigatran  
 From UFH, rivaroxaban therapy should 
be started once the UFH infusion has 
been stopped  
 To UFH, begin the continuous infusion 
UFH 24 hours after stopping the 
rivaroxaban 
Other parenteral 
anticoagulants  
 From another parenteral anticoagulant, 
start dabigatran within 2 hours of next 
scheduled dose of the discontinued agent  
 To another parenteral anticoagulant, 
discontinue dabigatran and initiate the 
anticoagulant based on estimated CrCl: 
o CrCl > 30 mL/min: wait 12 hours after 
last dose of dabigatran  
o CrCl 15-30 mL/min:  wait 24 hours 
after last dose of dabigatran 
 From another parenteral anticoagulant, 
initiate rivaroxaban within 2 hours of 
the next scheduled dose of the 
discontinued agent   
 To another parenteral anticoagulant, 
begin the anticoagulant 24 hours after 
stopping rivaroxaban 
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Table 2:  Baseline Characteristics 
  
 Dabigatran 
Encounters 
(n=78) 
Rivaroxaban 
Encounters 
(n=62)  
Mean age – years (SD) 66.9 ± 13.7 62.8 ± 13.7 
Male sex – n (%) 39 (50) 33 (53) 
Weight, kg – median (IQR) 87 (72-99) 94 (77-103) 
Creatinine Clearance – n (%) 
>50 mL/min  
30-50 mL/min 
< 30 mL/min 
 
55 (70.5) 
16 (20.5) 
7 (9) 
 
43 (69) 
16 (26) 
3 (5) 
SD = standard deviation; IQR = interquartile range 
 
 
 
 
Table 3: Indications for Use* 
 
 Dabigatran 
Encounters 
(n=78) 
% (n) 
Rivaroxaban 
Encounters 
(n=62)  
% (n) 
FDA Approved Indications 
Non-valvular atrial fibrillation  93 (73) 37 (23) 
Post-operative prophylaxis TKA - 39 (24) 
Post-operative prophylaxis THA -   6 (4) 
Non-FDA Approved Indications 
Prevention of recurrent VTE 7 (5) - 
Open reduction internal fixation prophylaxis - 8 (5) 
Peripheral vascular disease - 3 (2) 
DVT treatment - 2 (1) 
Paroxysmal supraventricular tachycardia - 2 (1) 
Genetic coagulopathies - 2 (1) 
Incision and drainage - 2 (1) 
TKA = total knee arthroplasty; THA = total hip arthroplasty; VTE = venous thromboembolism; DVT = 
deep vein thrombosis 
*FDA approved indications at the time of analysis (July 2012)  
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Table 4:  Dose and Dosing Adjustments 
 
 Dabigatran 
Encounters 
Rivaroxaban 
Encounters 
Doses administered per patient 
            Mean  
            Median (IQR) 
 
6.4 
5 (3-7) 
 
3.2 
3 (2-4) 
Anticoagulant orders, % (n) 
 
75 mg BID         83 (65) 
150 mg BID       16 (12) 
150 mg TID       1 (1) 
10 mg daily         55 (34) 
15 mg daily         21 (13) 
20 mg daily         24 (15) 
Doses administered, % (n) 75 mg                22 (107)             
150 mg              78 (387) 
10 mg                110 (56) 
15 mg                  37 (19) 
20 mg                  50 (25) 
Appropriate dose, % (n) 87 (68) 92 (57) 
Appropriate renal dose adjustment, % (n) 55 (6) 79 (15) 
 
 
 
 
 
 
 
Figure 1:  Transitioning Between Anticoagulant Therapy 
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